Research map: Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues

Back to the article

Papers in this map

  1. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis · Kiarash Riazi · 2022 · 2250 citations · Cited by this paper
  2. The relationship between iron deficiency and thyroid function: findings from a population-based study in Jordan · 2026 · Related
  3. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis · Stephen A. Harrison · 2024 · 1982 citations · Cited by this paper
  4. Exploring actions of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond glucose and obesity control: bone health and osteoporosis · 2026 · Related
  5. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline · Caroline M. Apovian · 2015 · 1348 citations · Cited by this paper
  6. The effects of levothyroxine monotherapy versus combination therapy on quality of life and patient satisfaction · 2025 · Related
  7. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension · John P.H. Wilding · 2022 · 1076 citations · Cited by this paper
  8. Possible attenuation of gout risk by SGLT-2 inhibitors in patients using thiazide and loop diuretics · 2025 · Related
  9. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis · Arun J. Sanyal · 2025 · 985 citations · Cited by this paper
  10. The intersection of education and health: schools as a catalyst for childhood obesity prevention · 2026 · Related
  11. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis · Stuart McPherson · 2016 · 945 citations · Cited by this paper
  12. Plasma vitamin D status and its association with biochemical, clinical and humanistic outcomes in diabetic foot infection patients: a prospective observational study in a tertiary healthcare facility · 2025 · Related
  13. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis · Rohit Seth Loomba · 2024 · 942 citations · Cited by this paper
  14. Moving away from BMI: a new era of diagnostic criteria in obesity · 2025 · Related
  15. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH · Sven Francque · 2021 · 779 citations · Cited by this paper
  16. Metabolic aspects of polycystic ovary syndrome · 2026 · Related
  17. Changing epidemiology, global trends and implications for outcomes of NAFLD · Vincent Wai‐Sun Wong · 2023 · 750 citations · Cited by this paper
  18. Serum asprosin and its association with bone mineral density, oxidative stress, and osteoprotegerin levels in Pakistani women with postmenopausal osteoporosis · 2025 · Related
  19. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis · Jingxuan Quek · 2022 · 744 citations · Cited by this paper
  20. Dialysis meets devices: the use of automated insulin delivery in end stage kidney disease and haemodialysis · 2026 · Related
  21. Direct effects of thyroid hormones on hepatic lipid metabolism · Rohit A. Sinha · 2018 · 673 citations · Cited by this paper
  22. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States · Zobair M. Younossi · 2020 · 583 citations · Cited by this paper
  23. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH · Rohit Seth Loomba · 2023 · 505 citations · Cited by this paper
  24. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss · Mohit Sodhi · 2023 · 455 citations · Cited by this paper
  25. Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies · Ian J. Neeland · 2024 · 382 citations · Cited by this paper
  26. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial · Donna H. Ryan · 2024 · 346 citations · Cited by this paper
  27. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus · Juan José Gorgojo Martínez · 2022 · 340 citations · Cited by this paper
  28. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis · Yasaman Vali · 2020 · 298 citations · Cited by this paper
  29. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials · Vanita R. Aroda · 2019 · 297 citations · Cited by this paper
  30. AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury · Robert J. Fontana · 2022 · 293 citations · Cited by this paper
  31. Safety of Semaglutide · Mark M. Smits · 2021 · 291 citations · Cited by this paper
  32. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials · Quentin Mark Anstee · 2019 · 276 citations · Cited by this paper
  33. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance · Vincent Lingzhi Chen · 2024 · 201 citations · Cited by this paper
  34. Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults · Herbert Tilg · 2025 · 197 citations · Cited by this paper
  35. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss · Sean Wharton · 2021 · 187 citations · Cited by this paper
  36. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis · Mazen Noureddin · 2024 · 162 citations · Cited by this paper
  37. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis · Jinho Jung · 2020 · 160 citations · Cited by this paper
  38. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease · Fasiha Kanwal · 2024 · 157 citations · Cited by this paper
  39. Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity · Jeffrey Ian Mechanick · 2024 · 139 citations · Cited by this paper

Source: OpenAlex (CC0)